Literature DB >> 12832511

Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice.

Anne Morinville1, Catherine M Cahill, M James Esdaile, Haneen Aibak, Brian Collier, Brigitte L Kieffer, Alain Beaudet.   

Abstract

We recently demonstrated that prolonged treatment with morphine increases the antinociceptive potency of the delta-opioid receptor (deltaOR) agonist deltorphin and promotes cell surface targeting of deltaORs in neurons of the dorsal horn of the rat spinal cord (Cahill et al., 2001b). In the present study we examined whether these effects were mediated selectively via muOR. Using the same intermittent treatment regimen as for morphine, we found that methadone and etorphine, but not fentanyl, enhanced [D-Ala2]-deltorphin-mediated antinociception. However, continuous delivery of fentanyl for 48 hr resulted in augmented deltaOR-mediated antinociception when compared with saline-infused animals. Time course studies confirmed that a 48 hr treatment with morphine was necessary for the establishment of enhanced deltaOR-mediated antinociception. The observed increases in deltaOR agonist potency and deltaOR plasma membrane density were reversed fully 48 hr after discontinuation of morphine injections. Wild-type C57BL/6 mice pretreated with morphine for 48 hr similarly displayed enhanced deltaOR-mediated antinociception in a tonic pain paradigm. Accordingly, the percentage of plasma membrane-associated deltaOR in the dorsal horn of the spinal cord, as assessed by immunogold electron microscopy, increased from 6.6% in naive to 12.4% in morphine-treated mice. In contrast, morphine treatment of muOR gene knock-out (KO) mice did not produce any change in deltaOR plasma membrane density. These results demonstrate that selective activation of muOR is critical for morphine-induced targeting of deltaOR to neuronal membranes, but not for basal targeting of this receptor to the cell surface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832511      PMCID: PMC6741164     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  58 in total

1.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

2.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

Review 3.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

5.  Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats.

Authors:  Audrey Normandin; Philippe Luccarini; Jean-Louis Molat; Louis Gendron; Radhouane Dallel
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

6.  Peripheral δ-opioid receptors attenuate the exercise pressor reflex.

Authors:  Anna K Leal; Katsuya Yamauchi; Joyce Kim; Victor Ruiz-Velasco; Marc P Kaufman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-09       Impact factor: 4.733

7.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

8.  Differential distributions and trafficking properties of dopamine D1 and D5 receptors in nerve cells.

Authors:  You He; Lei-Ping Yu; Guo-Zhang Jin
Journal:  Neurosci Bull       Date:  2009-04       Impact factor: 5.203

9.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

10.  Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn.

Authors:  Maureen S Riedl; Stephen A Schnell; Aaron C Overland; Anne-Julie Chabot-Doré; Anna M Taylor; Alfredo Ribeiro-da-Silva; Robert P Elde; George L Wilcox; Laura S Stone
Journal:  J Comp Neurol       Date:  2009-04-01       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.